论文部分内容阅读
c erbB 2表达于 2 0 %～ 30 %乳腺癌 ,它在预测乳腺癌病人的化疗反应性中起重要作用。乳腺癌病人c erbB 2过表达提示对某些化疗药物的耐受性或敏感性 ,c erbB 2可望作为乳腺癌化疗的生物学标志物 ,用于指导临床化疗
C erbB 2 is expressed in 20% -30% of breast cancers and plays an important role in predicting the chemoresponsiveness of breast cancer patients. Overexpression of c erbB 2 in breast cancer patients suggests resistance or susceptibility to certain chemotherapeutic drugs. C erbB 2 is expected to be used as a biomarker for breast cancer chemotherapy to guide clinical chemotherapy